Fenbendazole + Ivermectin: Evidence and Safety

Fenbendazole and ivermectin are often discussed together in online cancer forums. A proposed biological explanation for combining them is a research question, not proof of a useful treatment. The sources reviewed here do not establish this pairing as a safe or effective cancer regimen.

Evidence checked September 10, 2026. This review separates experiments, clinical research and reports of harm. It provides no dosing schedule or instructions to combine these compounds.

What the laboratory studies actually tested

Dogra and colleagues studied fenbendazole in cancer cells and mouse xenografts, reporting effects involving microtubules and cellular metabolism. Melotti and colleagues separately studied ivermectin and WNT-TCF signaling in cells and mice. Neither paper tests whether giving both compounds to cancer patients improves their outcomes. [1] [2]

These experiments can identify questions for further investigation. They cannot show that a person will respond, that two products work better together, or that exposures used in a laboratory can be reproduced safely in a patient.

Different mechanisms do not establish synergy

Describing one compound as affecting cell structure and another as affecting signaling does not measure their combined effect. A proposed combination needs to be studied as a combination. Researchers would need to examine outcomes and harms against suitable comparisons, rather than add together conclusions from separate experiments.

Clinical studies also have to distinguish the effect of the proposed combination from concurrent cancer care. The National Cancer Institute explains how comparison groups and random assignment help researchers make fairer assessments. A mechanistic diagram does not replace those comparisons. [5]

A related trial is not evidence for this pairing

NCT05318469 studies ivermectin with balstilimab or pembrolizumab in metastatic triple-negative breast cancer. It does not study fenbendazole plus ivermectin. The official record checked on September 10, 2026 was recruiting and had no posted registry results. It therefore cannot validate an online fenbendazole–ivermectin protocol. [3]

Evidence from a study of a different combination cannot simply be transferred to these two compounds. Similar drug names or a shared drug family do not establish interchangeable treatments. Always check exactly which substances, patients and outcomes a cited study includes.

Reports of harm belong in the assessment

A 2026 case report describes severe liver injury after a patient with prostate cancer used veterinary fenbendazole and ivermectin together. A case report cannot establish how frequently this happens or isolate each compound's contribution. It is nevertheless a reason not to treat an untested combination as harmless. [4]

Veterinary formulations should not be confused with approved human medicines. More generally, FDA explains that approval for one use does not establish safety and effectiveness for another. Calling a proposed cancer regimen “repurposed” does not settle its benefit-risk balance. [6]

Questions for the treating team

Does the research actually study both compounds together in people with this cancer?
What comparison was used, and what other treatments did participants receive?
Were outcomes independently assessed, and have corrections or editorial warnings been issued?
Is there a relevant registered trial with appropriate oversight?

If you have already used either compound, tell the treating clinician which products were involved and when. Do not replace or delay prescribed oncology care on the basis of an online combination chart.

What this evidence supports

The laboratory studies support further research questions. They do not provide a personal treatment plan, and combining their findings does not create one. For background, see our fenbendazole evidence review and ivermectin evidence review.